Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon

#MindfulMondays with Miss SA

teen suicide icon


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue1

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

NEW YORK (Reuters Health) Jan 24 - Certain non-diabetic patients with major depressive disorder show improved insulin sensitivity following treatment with amitriptyline or paroxetine, German researchers report.

In the December issue of the Journal of Clinical Psychiatry, Dr. Bettina Weber-Hamann of the Central Institute of Mental Health, Mannheim and colleagues note that there is substantial evidence that depression is a risk factor for type 2 diabetes.

The hypothalamus pituitary-adrenal (HPA) system may be involved, they suggest, and its activity could also be modified by antidepressant treatment.

To investigate further, the researchers conducted a double-blind study of 80 non-diabetic inpatients who had an episode of major depression. They were randomized to treatment with the tricyclic antidepressant amitriptyline, or the selective serotonin reuptake inhibitor paroxetine for 5 weeks.

In the amitriptyline group, 16 showed remission, 11 had a response, and 9 patients did not respond. The corresponding numbers in the paroxetine group were 17, 7 and 20.

Before and at the end of treatment, all patients were given an oral glucose tolerance test. After correction for body mass index, insulin sensitivity was seen to improve only in patients who showed remission with either drug.

In addition, following treatment, saliva cortisol concentrations fell only in amitriptyline patients in remission or who responded, suggesting, say the investigators, that the agent may reduce HPA system activity.

However, as Dr. Weber-Hamann pointed out in remarks to Reuters Health, "successful treatment with the serotonin reuptake inhibitor paroxetine similarly improved glucose utilization without affecting HPA system activity."

This, she concluded, underscores "the assumption that additional factors may play a role in regulating the sensitivity to insulin in patients with major depression."


Our Sponsors

Our Partners